Gongwin Biopharm Holdings Company Description

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore.

It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.

The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment.

Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Gongwin Biopharm Holdings Co., Ltd.

Country	Cayman Islands
Founded	2014
Industry	Biotechnology
Sector	Healthcare
CEO	Mao-Yuan Lin

Contact Details

Address: No. 80, Jianguo North Road Taipei, 10491 Taiwan
Phone	886 2 2503 5282
Website	gongwinbiopharm.com

Stock Details

Ticker Symbol	6617
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	KYG409471060
SIC Code	2836

Key Executives

Name	Position
Chonghan Wu Ph.D.	Founder and Chairman
Mao-Yuan Lin	GM and Director
Chang En Wang	Assistant Manager of Marketing Division
Rocky Shih	Co-Founder
Wei Nan Hu	Chief Financial Officer and Head of Administration Division
Wei Nan Hu	Accounting Director
Quan-Qing Yang	Deputy General Manager